Effect of hydrosoluble vitamin <scp>E</scp> on erythrocyte membrane lipid composition in patients with advanced cirrhosis: An open‐label pilot trial

Restellini, Sophie; Alaei, Maryam; Matthes, Thomas; Kherad, Omar; Moschetta, Antonio

doi:10.1111/hepr.12430

Cited by 3 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, Vitamin E supplementation was showed able to protect human erythrocyte membranes from OS and improve membrane fluidity and reducing hemolysis [54]. In addition, in patients with advanced cirrhosis, low vitamin E plasma levels are associted with abnormal erythrocyte membrane lipids, structural alterations and chronic hemolysis [55].…”

Section: Discussionmentioning

confidence: 99%

Study of Incubation Conditions for Erythrocytes Osmotic Fragility Testing in Dromedary Camel (Camelus dromedarius)

Islah¹,

Bargaa²,

Youssef³

et al. 2016

International Journal of Research in Environmental Science

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Study of Incubation Conditions for Erythrocytes Osmotic Fragility Testing in Dromedary Camel (Camelus dromedarius)

Islah¹,

Bargaa²,

Youssef³

et al. 2016

International Journal of Research in Environmental Science

View full text Add to dashboard Cite

show abstract

“…If the damage of the liver is not identified in the early stages, irreversible damage begins from hepatocyte degeneration and the liver goes to fibrosis and cirrhosis [ 53 ]. In cirrhosis, vitamin E levels have been found to be significantly low, and it is thought that vitamin E deficiency may play a role in cirrhosis etiopathogenesis [ 54 , 55 ].…”

Section: Discussionmentioning

confidence: 99%

Methotrexate-induced hepatotoxicity in rats and the therapeutic properties of vitamin E: a histopathologic and flowcytometric research

Akman,

Erisgin,

Turedi

et al. 2023

ceh

View full text Add to dashboard Cite

Aim of the study Methotrexate (MTX) causes oxidative stress-related liver damage. Our objective was to investigate the protective effects of vitamin E against MTX-induced hepatotoxicity through histopathological methods and flow cytometry. Material and methods The rats were assigned to four groups: Control (2 ml saline for 5 days), MTX (20 mg/kg intraperitoneally (i.p.) only on the initial day of the study), MTX + vitamin E (20 mg/kg MTX (i.p.) only on the first day, and 100 mg/kg vitamin E (i.p.) was applied for 5 days during the study), Vitamin E (100 mg/kg of vitamin E (i.p.) was given for five days). Histopathologic changes and the flow cytometric apoptotic index were evaluated for liver tissue. The Kruskal-Wallis test was used for comparisons between groups. The statistical significance level was accepted as p < 0.05. Results In the histopathological analysis, hepatocyte degeneration, dilatation of sinusoids, mononuclear cell infiltration, hydropic degeneration in hepatocytes, vacuolization, and pycnotic nucleus were observed in the MTX group. In the MTX + vitamin E group, hepatocyte degeneration, pycnotic nuclei, and dilatation in sinusoids were significantly lower compared to the MTX group. In the MTX group, glycogen accumulation in hepatocytes was lower compared to the control group. In the MTX + vitamin E group, glycogen accumulation in hepatocy-tes was higher compared to the MTX group. The flowcytometric apoptotic index (AI) percentage in the MTX group was 34.4% and in the MTX + vitamin E group the value was 9.4%. Conclusions Our results demonstrated that vitamin E ameliorates MTX-induced liver damage. Co-using vitamin E and MTX drugs will be beneficial for the treatment of various diseases.

show abstract

Efficacy of two vitamin E formulations in patients with abetalipoproteinemia and chylomicron retention disease

Cuerq

Hénin

Restier

et al. 2018

Journal of Lipid Research

View full text Add to dashboard Cite

and keywords AbstractAbetalipoproteinemia (ABL) and chylomicron retention disease (CMRD) are extremely rare recessive forms of hypobetalipoproteinemia characterized by intestinal lipid malabsorption and severe vitamin E deficiency. Vitamin E is often supplemented in the form of fat-soluble vitamin E acetate, but fat malabsorption considerably limits correction of the deficiency. In this crossover study, we administered two different forms of vitamin E -tocofersolan (a water-soluble derivative of RRR-α-tocopherol) and α-tocopherol acetate -to three patients with ABL and four with CMRD. The aims of this study were to evaluate the intestinal absorption characteristics of tocofersolan versus α-tocopherol acetate by measuring the plasma concentrations of α-tocopherol over time after a single oral load and to compare efficacy by evaluating the ability of each formulation to restore vitamin E storage after 4 months of treatment. In patients with ABL, tocofersolan and α-tocopherol acetate bioavailabilities were extremely low (2.8% and 3.1%, respectively). In contrast, bioavailabilities were higher in patients with CMRD (tocofersolan, 24.7%; α-tocopherol acetate, 11.4%). Plasma concentrations of α-tocopherol at 4 months were not significantly different by formulation type in ABL or CMRD. This study provides new insights about vitamin E status in ABL and CMRD and suggests the potential of different formulations as treatment options.

show abstract

Effect of hydrosoluble vitamin E on erythrocyte membrane lipid composition in patients with advanced cirrhosis: An open‐label pilot trial

Cited by 3 publications

References 27 publications

Study of Incubation Conditions for Erythrocytes Osmotic Fragility Testing in Dromedary Camel (Camelus dromedarius)

Study of Incubation Conditions for Erythrocytes Osmotic Fragility Testing in Dromedary Camel (Camelus dromedarius)

Methotrexate-induced hepatotoxicity in rats and the therapeutic properties of vitamin E: a histopathologic and flowcytometric research

Efficacy of two vitamin E formulations in patients with abetalipoproteinemia and chylomicron retention disease

Contact Info

Product

Resources

About